Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18053948 | 0.91 | MAPT (0.70) | MAPTPOLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL31586676 | 0.84 | MAPT (0.61) | MAPTPOLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL26705462 | 0.83 | MAPT (0.63) | MAPTPOLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL18053871 | 0.83 | POLB (0.68) | MAPTPOLBRAB9ACHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL25208089 | 0.82 | MAPT (0.62) | MAPTPOLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL4722950 | 0.82 | MAPT (0.58) | MAPTPOLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL20150158 | 0.82 | POLB (0.75) | MAPTPOLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL17054917 | 0.81 | MAPT (0.68) | MAPTPOLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL17054792 | 0.81 | MAPT (0.68) | MAPTPOLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL17054931 | 0.80 | MAPT (0.58) | MAPTPOLBRAB9ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-9340540-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340540-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015131080-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPT 1236/4885POLB 1657/4885RAB9A 3462/4885 |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPT 1236/4885POLB 1657/4885RAB9A 3462/4885 |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPT 1236/4885POLB 1657/4885RAB9A 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.